Isoniazid; rifampin - Generic Drug Details

What are the generic sources for isoniazid; rifampin and what is the scope of patent protection?

Isoniazid; rifampin is the generic ingredient in two branded drugs marketed by Sanofi Aventis Us and Hikma Intl Pharms, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for isoniazid; rifampin

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	56
DailyMed Link:	isoniazid; rifampin at DailyMed

Recent Clinical Trials for isoniazid; rifampin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	PHASE3
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE3
McGill University Health Centre/Research Institute of the McGill University Health Centre	PHASE2

See all isoniazid; rifampin clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for isoniazid; rifampin

J04AC	Hydrazides
J04A	DRUGS FOR TREATMENT OF TUBERCULOSIS
J04	ANTIMYCOBACTERIALS
J	Antiinfectives for systemic use

US Patents and Regulatory Information for isoniazid; rifampin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	RIFAMATE	isoniazid; rifampin	CAPSULE;ORAL	061884-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Hikma Intl Pharms	RIFAMPIN AND ISONIAZID	isoniazid; rifampin	CAPSULE;ORAL	065221-001	Jul 29, 2005		DISCN	No	No

Market Dynamics and Financial Trajectory for Isoniazid and Rifampin

Last updated: February 14, 2026

Market Overview

Isoniazid and rifampin are cornerstone antibiotics in the treatment of tuberculosis (TB). Their combination forms the backbone of first-line TB therapy. Global TB burden remains significant, with approximately 10 million cases annually and high mortality rates. Resistance to these drugs, particularly multidrug-resistant TB (MDR-TB), poses ongoing challenges.

Market Size and Growth Drivers

• Global TB Market: Valued at approximately $2 billion in 2022, with an expected CAGR of 4-6% over the next five years, driven by increasing TB incidence in Asia and Africa.
• Therapeutic Market Share: Isoniazid and rifampin account for roughly 60% of the TB drug market, owing to their widespread use in first-line regimens.
• Funding and Policy Influence: International agencies such as the Global Fund allocate billions annually ($4.2 billion in 2022) toward TB treatment programs, supporting drug demand.

Market Segmentation

• By Region: Asia-Pacific leads market share (~50%), followed by Africa (~20%), Eastern Europe (~10%), and the Americas (~20%).
• By Formulation: Oral tablets dominate, with fixed-dose combinations (FDCs) increasingly adopted to improve adherence.
• By Patient Population: Adults constitute approximately 85% of cases; pediatric TB treatment relies on modified dosages and formulations.

Supply Chain and Production

• Manufacturers: GSK, Sanofi, and Lupin are principal producers of rifampin; isoniazid is produced by numerous generic companies.
• Patents and Generics: Isoniazid and rifampin are off-patent; generic availability is high, lowering costs and increasing access.
• Supply Risks: Manufacturing shortages can occur during pandemics or geopolitical disruptions, affecting global availability.

Market Challenges

• Drug Resistance: MDR-TB and extensively drug-resistant (XDR) TB strains undermine treatment efficacy, prompting the need for new drugs and regimens.
• Adherence Issues: Long treatment durations (~6 months) with significant side effects reduce compliance.
• Funding Fluctuations: Dependence on international aid creates vulnerability to funding cuts.

Financial Trajectory

• Pricing Trends: Generic rifampin costs dropped below $0.10 per tablet; isoniazid remains similarly low-cost.
• Market Revenues: Estimated to grow from $2 billion in 2022 to around $2.4-$2.5 billion by 2027, contingent on TB incidence and treatment adherence rates.
• Investment in R&D: Limited pipeline of new TB drugs; however, dedicated R&D funding from organizations like the Global Alliance for TB Drug Development supports incremental innovations.

Future Market Outlook

• Emerging Technologies: Focus on shorter regimens, injectable-free therapies, and combination FDCs.
• Regulatory Environment: WHO's endorsement of new regimens influences prescribing practices and market dynamics.
• Potential Disruptors: Development of novel TB drugs (e.g., pretomanid, bedaquiline) could shift market share and treatment paradigms, possibly reducing reliance on traditional drugs like isoniazid and rifampin.

Key Drivers and Risks

Drivers	Risks
Continued global TB incidence growth	Rise of drug-resistant strains
International funding stability	Shortage in drug supply due to manufacturing or geopolitical issues
Adoption of FDCs to improve adherence	Slow adoption of new regimens due to regulatory or operational hurdles
Advances in treatment protocols	Increased costs or delays in pipeline approval

---

Key Takeaways

• Isoniazid and rifampin hold dominant positions in TB treatment, with sustained demand driven by global TB prevalence.
• Cost reductions, generic competition, and international health programs support accessible treatment but pose challenges for profit margins.
• Market growth remains steady, supported by ongoing TB incidence and policy endorsements, although emerging resistance and drug development slowdowns could impact long-term outlooks.
• Innovations focusing on shorter, more tolerable regimens could alter current market dynamics.

---

Frequently Asked Questions

1. What factors influence the cost of isoniazid and rifampin in global markets?
   Price is affected by patent status, generic competition, manufacturing costs, and international procurement policies. Generic availability keeps prices low, especially in developing countries.

2. How does drug resistance impact market demand for these drugs?
   Resistance reduces efficacy, necessitating alternative or combination therapies, which may alter demand patterns and stimulate R&D in new drugs.

3. What role do international agencies play in shaping the market?
   They fund procurement, set treatment guidelines, and influence policy, directly impacting demand and adoption rates of specific regimens.

4. Are there significant technological innovations expected for TB with these drugs?
   Focus remains on shorter regimens, fixed-dose combinations, and injectable-free therapies. Developments may reduce reliance on traditional drugs like isoniazid and rifampin.

5. What are the main challenges in expanding access to TB treatment using these drugs?
   Challenges include drug resistance, long treatment durations affecting adherence, supply chain disruptions, and limited funding for endemic regions.

---

Citations

1. WHO Global Tuberculosis Report 2022
2. IMS Health Market Analytics, 2022
3. Global Fund TB Grant Data, 2022
4. GSK, Sanofi product data and patent status disclosures
5. TB Alliance Pipeline and Innovation Updates